GlycoEra Ltd, a Swiss biotechnology company developing extracellular protein degraders for the treatment of autoimmune diseases, has closed a USD 130 million Series B financing. The oversubscribed round was led by Novo Holdings, with participation from additional new investors LifeArc Ventures, Catalio Capital Management, QIA, MP Healthcare Venture Management, Sixty Degree Capital and Agent Capital. Existing investors, including Sofinnova Partners, 5AM Ventures, Roche Ventures and Bristol Myers Squibb, also participated.
Max Klement (partner, Novo Holdings), Matthew Hobson (principal, Catalio Capital Management) and Sohaib Mir (partner, LifeArc Ventures) will join the board of directors of GlycoEra.
act legal Switzerland (formerly BGPartner Ltd) advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss law aspects and the negotiations of this Series B financing round. The team consisted of Oliver Gnehm, Victoria Marty, Tessa Douma and Anja Spahni.












